• Sulfaphenazole: Bridging CYP2C9 Inhibition to Translational

  2026-05-31

  Explore how Sulfaphenazole’s selective CYP2C9 inhibition and antibacterial action are redefining translational research—from mechanistic insight to practical guidance for drug metabolism, vascular function, and infectious disease models. This article synthesizes the latest structure-activity findings, protocol recommendations, and cross-domain opportunities, providing actionable strategies for research leaders.

• D-Luciferin Sodium Salt: Precision Tools for Quantitative On

  2026-05-30

  Explore how D-Luciferin sodium salt enables precise, quantitative bioluminescence imaging in oncology and immunotherapy research. This article uniquely dissects assay optimization and translational workflow design, providing practical insights for advanced applications.

• Applied Workflows with EZ Cap Cy5 Firefly Luciferase mRNA (5

  2026-05-29

  EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) empowers researchers with dual-mode tracking for mRNA delivery and translation, optimizing both fluorescent and bioluminescent readouts. This guide translates recent advances and practical insights into actionable protocols, troubleshooting, and innovative applications for high-fidelity gene expression and imaging.

• Thioguanine Applications: Protocol Enhancements and Troubles

  2026-05-29

  Thioguanine (6-thioguanine) stands apart as a dual-purpose compound for cancer and antiviral research, enabling robust workflows targeting DNA synthesis and epigenetic modulation. Discover how APExBIO’s high-purity formulation empowers reproducibility, advanced assay design, and effective troubleshooting in preclinical studies.

• Alternariol in Mycotoxin Research: Protocols, Pitfalls & Inn

  2026-05-28

  Alternariol (AOH) is reshaping mycotoxin research, providing mechanistic clarity for liver fibrosis and apoptosis pathways. This article delivers protocol-driven insights, troubleshooting tips, and practical workflow enhancements to help researchers leverage APExBIO’s Alternariol for advanced cytochrome P450 enzyme assays and translational toxin studies.

• AZ505 and SMYD2 Inhibition: Unveiling New Horizons in Epigen

  2026-05-28

  Explore the unique mechanism and translational potential of AZ505, a potent SMYD2 inhibitor, in both epigenetic regulation and renal fibrosis models. Gain in-depth insights not found in typical workflow guides and discover new directions for cancer and kidney disease research.

• JHU-083: Applied Glutaminase Antagonism for Disease Models

  2026-05-27

  JHU-083, a potent 6-diazo-5-oxo-L-norleucine precursor, enables precise glutaminase inhibition in neurological and experimental cerebral malaria models. This guide details robust protocols, experimental insights, and troubleshooting tips to maximize reproducibility and reveal new avenues in glutaminase pathway research.

• Enhancing Proteotoxic Cell Death in Prostate Cancer with Dua

  2026-05-27

  This study demonstrates that combining the cyclophilin inhibitor rencofilstat with the proteasome inhibitor ixazomib selectively increases apoptotic cell death in advanced prostate cancer cells, while sparing non-cancerous cells. These findings highlight a promising strategy for overcoming therapeutic resistance and increasing cancer cell sensitivity to proteotoxic stress.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe Gui

  2026-05-26

  DiI (DiIC18(3)) addresses the need for robust, high-contrast plasma membrane labeling in workflows such as neuronal tracing and cell migration assays. This probe should not be used for intracellular organelle labeling or in aqueous staining protocols, as its lipophilic nature and solubility profile restrict effective use to membrane environments.

• SGI-1027 Modulates DNMT1 and RB1 to Suppress Gastric Cancer

  2026-05-26

  This study demonstrates that SGI-1027, a DNA methyltransferase inhibitor, downregulates DNMT1 and restores RB1 expression, leading to reduced proliferation and metastasis in gastric cancer models. The findings clarify the mechanistic link between epigenetic modulation and tumor suppressor gene reactivation, offering actionable insights for cancer epigenetics research.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Practical Lab Guide

  2026-05-25

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) addresses the need for reliable, cross-species detection of HMGB1 in Western blot, immunohistochemistry, and flow cytometry workflows. This tool is not validated for diagnostic or therapeutic use and should only be employed in basic research settings.

• Crystallizing the DDX3 RNA Helicase Domain: Methodological A

  2026-05-25

  This study presents the first successful crystallization and X-ray diffraction analysis of the human DDX3 RNA helicase domain, a DEAD-box protein implicated in RNA metabolism and disease. The work distinctly demonstrates the role of spermine tetrahydrochloride as a protein crystallization additive, providing structural biologists with key parameters for reproducible results.

• SM-102 in mRNA Vaccine Delivery: Workflow, Optimization, and

  2026-05-24

  SM-102 is a high-purity synthetic lipid crucial for forming lipid nanoparticles in mRNA vaccine delivery systems, enabling efficient cellular uptake and endosomal escape. This article distills advanced workflow strategies, protocol parameters, and troubleshooting insights, drawing from recent machine learning-driven research and hands-on experimental experience, to help researchers achieve robust and reproducible results.

• Translating p53 Modulation: Strategic Use of JNJ-26854165

  2026-05-23

  This thought-leadership article examines how JNJ-26854165 (Serdemetan), a potent HDM2 ubiquitin ligase antagonist, is reshaping translational cancer research. Integrating mechanistic insights and strategic workflow guidance, it bridges in vitro rigor with clinical relevance. Researchers will discover advanced protocols, competitive context, and actionable recommendations for leveraging Serdemetan in p53 pathway modulation, anti-proliferative, apoptosis, and radiosensitization studies. The discussion synthesizes recent advances in drug response metrics and highlights how APExBIO’s offering enables reproducible, high-impact research.

• Dual-Action Inhibitors Enhance Dephosphorylation of p38α MAP

  2026-05-22

  The reference study uncovers how certain kinase inhibitors not only block p38α MAP kinase activity but also promote its dephosphorylation by stabilizing an activation loop conformation accessible to phosphatases. This dual-action mechanism offers a new strategy for improving specificity and efficacy in inflammation and vascular research.

16567 records 1/1105 page Next 12345 下5页 Last page